{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:21:48Z","timestamp":1767853308007,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ibroneuroreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IBRO Neuroscience Reports"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ibneur.2023.06.007","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T12:29:48Z","timestamp":1688473788000},"page":"90-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study"],"prefix":"10.1016","volume":"15","author":[{"given":"Kadalraja","family":"Raghavan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidyasagar Devaprasad","family":"Dedeepiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramaniam","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramanian","family":"Pushkala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhakar S.","family":"Bharatidasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobunao","family":"Ikewaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-8744","authenticated-orcid":false,"given":"Masaru","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajappa","family":"Senthilkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthilkumar","family":"Preethy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-2687","authenticated-orcid":false,"given":"Samuel J.K.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ibneur.2023.06.007_bib1","unstructured":"M.R.C. Muscle Scale. \u3008https:\/\/mrc.ukri.org\/research\/facilities-and-resources-for-researchers\/mrc-scales\/mrc-muscle-scale\/\u3009 (Accessed: December 13, 2021)."},{"issue":"2","key":"10.1016\/j.ibneur.2023.06.007_bib2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0022-510X(92)90294-U","article-title":"A homologue of dystrophin is expressed at the blood vessel membrane of DMD and BMD patients: immunological evidence","volume":"107","author":"Augier","year":"1992","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ibneur.2023.06.007_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cca.2017.11.024","article-title":"Diagnostic and clinical significance of the titin fragment in urine of Duchenne muscular dystrophy patients","volume":"476","author":"Awano","year":"2018","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/j.ibneur.2023.06.007_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/brainsci10040234","article-title":"Microbiome in multiple sclerosis; where are we, what we know and do not know","volume":"10","author":"Boziki","year":"2020","journal-title":"Brain Sci."},{"issue":"17","key":"10.1016\/j.ibneur.2023.06.007_bib5","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1111\/febs.12266","article-title":"Modifying muscular dystrophy through transforming growth factor-\u03b2","volume":"280","author":"Ceco","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.ibneur.2023.06.007_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/895370","article-title":"Potential effects of nichi glucan as a food supplement for diabetes mellitus and hyperlipidemia: preliminary findings from the study on three patients from India","volume":"2012","author":"Dedeepiya","year":"2012","journal-title":"Case Rep. Med"},{"issue":"10","key":"10.1016\/j.ibneur.2023.06.007_bib7","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.ibneur.2023.06.007_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","article-title":"Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy","volume":"27","author":"Dzierlega","year":"2020","journal-title":"Gene Ther."},{"issue":"R2","key":"10.1016\/j.ibneur.2023.06.007_bib9","doi-asserted-by":"crossref","first-page":"R163","DOI":"10.1093\/hmg\/ddy171","article-title":"Exon-skipping advances for Duchenne muscular dystrophy","volume":"27","author":"Echevarr\u00eda","year":"2018","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.ibneur.2023.06.007_bib10","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.12688\/f1000research.15889.2","article-title":"The root cause of Duchenne muscular dystrophy is the lack of dystrophin in smooth muscle of blood vessels rather than in skeletal muscle per se","volume":"7","author":"Gajendran","year":"2018","journal-title":"F1000Research"},{"issue":"1","key":"10.1016\/j.ibneur.2023.06.007_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/19390211.2013.859211","article-title":"Beneficial effects of Black yeast derived 1-3, 1-6 beta glucan- Nichi Glucan in a dyslipidemic individual of Indian origin - A case report","volume":"11","author":"Ganesh","year":"2014","journal-title":"J. Diet. Suppl."},{"issue":"1","key":"10.1016\/j.ibneur.2023.06.007_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.nmd.2007.07.006","article-title":"Myoglobinuria in boys with Duchenne muscular dystrophy on corticosteroid therapy","volume":"18","author":"Garrood","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ibneur.2023.06.007_bib13","doi-asserted-by":"crossref","unstructured":"Ikewaki N., Ikeue Y., Nagataki M., Kurosawa G., Dedeepiya V.D., Rajmohan M., Suryaprakash V., Senthilkumar R., Preethy S. Abraham S.J.K. Beneficial effects of 1,3\u20131,6 \u03b2-glucans produced by Aureobasidium pullulans on non-esterified fatty acid levels in diabetic KKAy mice and their potential implications in metabolic dysregulation. J Diabetes Metab Disord (2022).","DOI":"10.1101\/2021.07.22.453362"},{"issue":"6","key":"10.1016\/j.ibneur.2023.06.007_bib14","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.jceh.2022.06.008","article-title":"Hepatoprotective Effects of Aureobasidium pullulans Derived \u03b2 1,3-1,6 Glucans in a Murine Model of Non-alcoholic Steatohepatitis","volume":"12","author":"Ikewaki","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.ibneur.2023.06.007_bib15","article-title":"Immune and metabolic beneficial effects of Beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans in healthy middle-aged Japanese men: An exploratory study","author":"Ikewaki","year":"2021","journal-title":"medRxiv"},{"issue":"14","key":"10.1016\/j.ibneur.2023.06.007_bib16","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/hmg\/ddl151","article-title":"Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice","volume":"15","author":"Ito","year":"2006","journal-title":"Hum. Mol. Genet"},{"issue":"6","key":"10.1016\/j.ibneur.2023.06.007_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","article-title":"Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011","volume":"56","author":"Kieny","year":"2013","journal-title":"Ann. Phys. Rehabil. Med"},{"issue":"1","key":"10.1016\/j.ibneur.2023.06.007_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-021-01758-9","article-title":"Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?","volume":"16","author":"Kourakis","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.ibneur.2023.06.007_bib19","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/nu13030998","article-title":"Nutraceutical screening in a zebrafish model of muscular dystrophy: gingerol as a possible food aid","volume":"13","author":"Licitra","year":"2021","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.ibneur.2023.06.007_bib20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ebiom.2015.03.018","article-title":"IL-6 blockade as a therapeutic approach for duchenne muscular dystrophy","volume":"2","author":"Mammen","year":"2015","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ibneur.2023.06.007_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2044-5040-1-21","article-title":"Aberrant repair and fibrosis development in skeletal muscle","volume":"1","author":"Mann","year":"2011","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.ibneur.2023.06.007_bib22","first-page":"CD003725","article-title":"Glucocorticoid corticosteroids for Duchenne muscular dystrophy","volume":"2","author":"Manzur","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.ibneur.2023.06.007_bib23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mus.21544","article-title":"The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy","volume":"41","author":"McDonald","year":"2010","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.ibneur.2023.06.007_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2012.04.078","article-title":"Gene therapy for muscular dystrophy: lessons learned and path forward","volume":"527","author":"Mendell","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ibneur.2023.06.007_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12883-015-0408-z","article-title":"Improving clinical trial design for Duchenne muscular dystrophy","volume":"15","author":"Merlini","year":"2015","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.ibneur.2023.06.007_bib26","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1186\/s13063-019-3740-6","article-title":"Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial","volume":"20","author":"Nagy","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.ibneur.2023.06.007_bib27","unstructured":"National Institute of Arthritis and Musculoskeletal and Skin Diseases. Spotlight on Research: Optimizing Steroid Treatment for Duchenne Muscular Dystrophy https:\/\/www.niams.nih.gov\/newsroom\/spotlight-on-research\/optimizing-steroid-treatment-duchenne-muscular-dystrophy (Accessed: December 13, 2021)."},{"issue":"22","key":"10.1016\/j.ibneur.2023.06.007_bib28","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2004840117","article-title":"Toward the correction of muscular dystrophy by gene editing","volume":"118","author":"Olson","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.ibneur.2023.06.007_bib29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ebiom.2015.02.014","article-title":"Functional and morphological improvement of dystrophic muscle by interleukin 6 receptor blockade","volume":"2","author":"Pelosi","year":"2015","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ibneur.2023.06.007_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2022-000985","article-title":"Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential applications in human health and disease","volume":"9","author":"Preethy","year":"2022","journal-title":"BMJ Open Gastroenterol."},{"key":"10.1016\/j.ibneur.2023.06.007_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112243","article-title":"Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study","volume":"145","author":"Raghavan","year":"2022","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.ibneur.2023.06.007_bib32","article-title":"Benefits of gut microbiota reconstitution by beta 1,3-1,6 glucans in subjects with autism spectrum disorder and other neurodegenerative diseases","author":"Raghavan","year":"2022","journal-title":"J. Alzheimers Dis."},{"issue":"26","key":"10.1016\/j.ibneur.2023.06.007_bib33","doi-asserted-by":"crossref","first-page":"eabh3693","DOI":"10.1126\/sciadv.abh3693","article-title":"Anti-inflammatory nanoparticles significantly improve muscle function in a murine model of advanced muscular dystrophy","volume":"7","author":"Raimondo","year":"2021","journal-title":"Sci. Adv."},{"issue":"299","key":"10.1016\/j.ibneur.2023.06.007_bib34","doi-asserted-by":"crossref","first-page":"299rv4","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated pathology in Duchenne muscular dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Sci. Transl. Med"},{"issue":"1","key":"10.1016\/j.ibneur.2023.06.007_bib35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ibneur.2023.06.007_bib36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pri.520","article-title":"North star clinical network for paediatric neuromuscular disease. development of a functional assessment scale for ambulatory boys with duchenne muscular dystrophy","volume":"17","author":"Scott","year":"2012","journal-title":"Physiother. Res Int"},{"issue":"1","key":"10.1016\/j.ibneur.2023.06.007_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jpm9010001","article-title":"Restoring dystrophin expression in duchenne muscular dystrophy: current status of therapeutic approaches","volume":"9","author":"Shimizu-Motohashi","year":"2019","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.ibneur.2023.06.007_bib38","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fphys.2015.00283","article-title":"Satellite cells in human skeletal muscle plasticity","volume":"6","author":"Snijders","year":"2015","journal-title":"Front Physiol."},{"key":"10.1016\/j.ibneur.2023.06.007_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155134","article-title":"Interleukin-6: A neuro-active cytokine contributing to cognitive impairment in Duchenne muscular dystrophy?","volume":"133","author":"Stephenson","year":"2020","journal-title":"Cytokine"},{"issue":"3\u20134","key":"10.1016\/j.ibneur.2023.06.007_bib40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000369343","article-title":"Prevalence of muscular dystrophies: a systematic literature review","volume":"43","author":"Theadom","year":"2014","journal-title":"Neuroepidemiology"},{"issue":"11","key":"10.1016\/j.ibneur.2023.06.007_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049350","article-title":"Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy","volume":"7","author":"Thomas","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ibneur.2023.06.007_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10974-019-09535-9","article-title":"What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?","volume":"40","author":"Wells","year":"2019","journal-title":"J. Muscle Res Cell Motil."}],"container-title":["IBRO Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667242123000556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667242123000556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:02:58Z","timestamp":1762642978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667242123000556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":42,"alternative-id":["S2667242123000556"],"URL":"https:\/\/doi.org\/10.1016\/j.ibneur.2023.06.007","relation":{},"ISSN":["2667-2421"],"issn-type":[{"value":"2667-2421","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study","name":"articletitle","label":"Article Title"},{"value":"IBRO Neuroscience Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ibneur.2023.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of International Brain Research Organization.","name":"copyright","label":"Copyright"}]}}